CagriSema Australia: What It Is (2026)

The short answer

CagriSema is the working name for an investigational fixed combination of two compounds, cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), developed by Novo Nordisk. As of 2026 it is still in clinical trials and is not an approved product.

In Australia, CagriSema as a combination is not approved by the Therapeutic Goods Administration (TGA) and is not on the Australian Register of Therapeutic Goods (ARTG). It remains investigational here. Everything below is a factual overview for context only.

What CagriSema actually is

CagriSema is a single-product combination of two separate molecules delivered together. The first is cagrilintide, described in the published literature as a long-acting amylin analogue. The second is semaglutide, a GLP-1 receptor agonist that is already familiar under other brand names when used for approved indications.

The idea behind combining them is to engage two different biological signalling pathways at once rather than one. Because the two components act through different receptor systems, the combination is studied as a dual-pathway candidate in metabolic research. It is important to be clear that CagriSema itself, as the fixed combination, is a single investigational candidate and not yet a registered medicine anywhere.

The two components

• Cagrilintide: a long-acting amylin analogue studied in obesity and metabolic research.
• Semaglutide: a GLP-1 receptor agonist, approved under other brand names for certain uses but studied here only as part of the combination.

The dual-pathway idea

The scientific rationale for CagriSema rests on two mechanisms being investigated together. Amylin analogues such as cagrilintide are reported in the literature to act on satiety-related signalling, including circuits in the area postrema and hypothalamus, and to influence gastric emptying. GLP-1 receptor agonists such as semaglutide act through the incretin pathway.

Researchers are interested in whether engaging the amylin pathway and the GLP-1 pathway at the same time produces effects that differ from either pathway alone. This is a research question being tested in trials, not an established fact, and nothing here should be read as a claim about outcomes in people.

Where it sits in clinical trials

CagriSema has been studied in a phase 3 clinical programme run by Novo Nordisk, publicly referred to as the REDEFINE programme, alongside other named studies. These trials have been conducted in adults with overweight or obesity and in people with type 2 diabetes, and the programme includes multiple separate trials reading out at different times.

Publicly reported results have been mixed. Novo Nordisk reported that in a head-to-head trial the combination did not meet a particular primary endpoint against a comparator, while other trials in the programme have been the basis for a regulatory submission. The company submitted CagriSema for obesity to the United States Food and Drug Administration in late 2025, with a decision anticipated later in the review cycle. Further trials, including cardiovascular outcome and higher-dose studies, were reported as ongoing or planned.

The key point for an Australian reader is simply that the programme is still active and results are still being generated. We deliberately do not summarise specific efficacy figures here, because trial outcomes are being interpreted, updated and debated, and quoting them out of context would risk overstating what is known.

Australian regulatory status

As of 2026, CagriSema as a combination product is not approved by the TGA and is not listed on the ARTG. There is no publicly indicated TGA registration for the combination at this time, and it remains investigational in Australia. An approval in another country, if and when it occurs, does not by itself create an Australian approval.

It is worth separating the combination from its components. Semaglutide is approved in Australia under certain brand names for certain approved uses, which is a separate matter from the CagriSema combination. The approval of a component does not mean the combination is approved. Cagrilintide, the amylin component, is not an approved finished medicine in Australia.

On scheduling, we do not state a specific Poisons Standard schedule for cagrilintide here because we could not confirm one from a primary regulatory source at the time of writing. Scheduling and regulatory classification can change, and the authoritative position is whatever the TGA and the current Poisons Standard say. If this matters to your situation, check the TGA directly or seek professional advice.

What research use only means

When a compound is described as being for research use only (RUO), it means the material is intended for laboratory research and not for human or veterinary use, not for diagnosis, and not for treatment. An RUO label is a statement of intended use, not a workaround for approval requirements.

Research use only, in practice

• Intended for laboratory and scientific research only.
• Not for human or animal consumption or administration.
• Not a medicine and not a substitute for an approved product.
• Not accompanied by dosing instructions or therapeutic claims.

Reading claims about CagriSema online

Because CagriSema has had a high public profile, there is a lot of commentary online, and not all of it is careful. Some sources blur the line between an investigational candidate and an available product, or quote trial figures without the context that explains them.

A neutral approach is to treat the regulator position as the anchor. If a product is not on the ARTG, it is not an approved Australian medicine, regardless of how it is described elsewhere. Marketing language, overseas timelines and social media summaries are not substitutes for the official record.

Sensible checks

• Is the exact product on the ARTG, or only a different component?
• Is a quoted result from a primary trial report or a secondhand summary?
• Does the source separate investigational status from approved status?
• Is the claim about laboratory research, or is it implying human use?

How NovaPeptides handles research compounds

NovaPeptides supplies research compounds for laboratory research use only. We do not sell CagriSema, or any compound, as a medicine, and we make no therapeutic or efficacy claims. Nothing on this page is an offer to supply an unapproved therapeutic good for use in people.

Where research compounds are supplied, they are accompanied by a third-party certificate of analysis from Novagen, shipping is within Australia, and enquiries are handled via WhatsApp. If you are a researcher, the certificate of analysis is the document that describes identity and purity for the specific material.

Frequently asked questions

Related guides